Drug Sales Trends for NEURONTIN

Payment Methods and Pharmacy Types for NEURONTIN (2022)

Revenues by Pharmacy Type

Pharmacy Type	Revenues
INSIDE HMO/CLINIC/HOSPITAL	$37,994,853

Units Sold by Pharmacy Type

Pharmacy Type	Units
INSIDE HMO/CLINIC/HOSPITAL	10,946

Revenues by Payment Method

Payment Method	Revenues
OTHER FEDERAL	$37,912,318
SELF OR FAMILY	$82,535

Select year for charts:

[2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ]

Annual Sales Revenues and Units Sold for NEURONTIN

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
NEURONTIN			2022
NEURONTIN			2021
NEURONTIN			2020
NEURONTIN			2019
NEURONTIN			2018
NEURONTIN			2017
NEURONTIN			2016

NEURONTIN (Gabapentin) Market Analysis and Sales Projections

Last updated: February 19, 2026

Neurontin, the brand-name formulation of gabapentin, is an anticonvulsant medication primarily prescribed for epilepsy and neuropathic pain. Its market performance is influenced by patent expiries, generic competition, evolving therapeutic guidelines, and the emergence of newer treatment modalities.

What is the Current Market Status of Neurontin?

Neurontin's market presence has significantly shifted since its original patent expiry. The introduction of generic gabapentin has led to a substantial decline in brand-name sales. However, gabapentin remains a widely prescribed medication across various indications.

• Peak Sales: Neurontin, under Pfizer's ownership, achieved peak annual sales exceeding $2 billion [1].
• Generic Entry: The primary U.S. patent for gabapentin expired in 2000, leading to the widespread availability of generic versions [2].
• Market Share: While brand-name Neurontin's market share is minimal, gabapentin as a molecule continues to hold a significant position in the anticonvulsant and neuropathic pain markets. It is estimated that gabapentin prescriptions numbered over 23 million in the U.S. annually in recent years [3].
• Indications: Approved indications for Neurontin include adjunctive therapy for partial seizures in patients 12 years of age and older, and postherpetic neuralgia (PHN) in adults [4]. Off-label uses are extensive, including fibromyalgia, restless legs syndrome, and anxiety disorders.

Who are the Key Market Players and Competitors?

The market for gabapentin is characterized by a large number of generic manufacturers, alongside the original brand owner, Pfizer, which continues to market Neurontin.

• Brand-Name Manufacturer: Pfizer Inc. [1]
• Major Generic Manufacturers: Numerous pharmaceutical companies produce generic gabapentin. These include, but are not limited to:
  • Teva Pharmaceuticals
  • Mylan N.V. (now Viatris)
  • Sun Pharmaceutical Industries
  • Lupin Pharmaceuticals
  • Apotex Inc.
• Therapeutic Class Competitors: While direct competition for the gabapentin molecule is primarily from generics, other drug classes compete for the same patient population:
  • Other Anticonvulsants: Pregabalin (Lyrica), lamotrigine, topiramate.
  • Neuropathic Pain Agents: Duloxetine, amitriptyline, tapentadol, pregabalin.
  • Opioids: While increasingly scrutinized, opioids remain a treatment option for severe pain.

What are the Patent Expirations and Intellectual Property Landscape?

Neurontin's intellectual property history is critical to understanding its market trajectory. The expiration of its core patents opened the door for genericization.

• Core U.S. Patent Expiry: The primary U.S. patent covering gabapentin's composition of matter expired in 2000 [2].
• Formulation and Method of Use Patents: While composition of matter patents have expired, pharmaceutical companies may hold patents on specific formulations, delivery systems, or methods of using gabapentin for particular indications. However, these are generally less impactful than composition patents in the long term.
• Data Exclusivity: For new indications or formulations approved by regulatory bodies, periods of data exclusivity may apply. However, for the original Neurontin product, these periods have long since passed.
• Patent Litigation: Pfizer engaged in extensive litigation to defend its patents. However, the U.S. Supreme Court's decision in Warner-Lambert Co. v. Teva Pharmaceuticals USA, Inc. (2003) regarding the breadth of patent claims was significant in paving the way for generic entry [5].

What are the Sales Projections for Neurontin and Generic Gabapentin?

Forecasting brand-name Neurontin sales is challenging due to its de minimis market share in the face of widespread generic availability. Projections focus on the broader gabapentin market.

• Brand-Name Neurontin: Sales of branded Neurontin are projected to remain negligible. Future growth is unlikely beyond niche markets or specific regional availability.
• Generic Gabapentin Market: The market for generic gabapentin is expected to remain robust, driven by its established efficacy, broad therapeutic utility, and cost-effectiveness compared to newer agents.
  • Market Size: The global gabapentin market was valued at approximately $1.5 billion in 2022 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 3-5% from 2023 to 2030 [6]. This growth is primarily attributed to the sustained demand for generic formulations.
  • Key Drivers:
    • Increasing prevalence of neurological disorders: Epilepsy and neuropathic pain conditions are significant drivers of gabapentin demand.
    • Cost-effectiveness: Generic gabapentin offers a lower price point than many branded alternatives, making it a preferred choice for healthcare systems and patients.
    • Established treatment profile: Decades of clinical use have solidified gabapentin's role in treatment algorithms.
    • Off-label prescription growth: Continued exploration and acceptance of gabapentin for various pain and neurological conditions contribute to prescription volume.
  • Potential Restraints:
    • Side effect profile: Dizziness, somnolence, and potential for abuse or misuse can limit its use.
    • Emergence of novel therapies: Development of new drugs with improved efficacy or safety profiles could impact gabapentin's market share.
    • Regulatory scrutiny: Concerns regarding gabapentinoid prescribing patterns and potential misuse may lead to stricter prescribing guidelines in some regions.
• Projected U.S. Prescription Volume (Gabapentin): Current trends suggest stable to slightly increasing prescription volumes in the U.S., potentially reaching 25-27 million prescriptions annually by 2028, largely driven by off-label use and a stable base for approved indications.

What are the Regulatory and Clinical Considerations?

Regulatory actions and evolving clinical practices significantly impact gabapentin's market.

• FDA Approvals:
  • Neurontin (Gabapentin) Capsules: Approved by the U.S. Food and Drug Administration (FDA) in 1993 [4].
  • Indications:
    • Adjunctive therapy for partial seizures in patients 12 years and older.
    • Treatment of postherpetic neuralgia (PHN) in adults.
• European Medicines Agency (EMA) Approvals: Gabapentin is also approved in Europe for similar indications.
• Prescribing Guidelines and Warnings:
  • Abuse and Misuse Potential: Regulatory bodies, including the FDA, have issued warnings about the potential for abuse, misuse, and diversion of gabapentinoids. This has led to increased pharmacovigilance and, in some jurisdictions, recommendations for cautious prescribing and monitoring [7].
  • Opioid Co-Prescribing: Studies have highlighted concerns regarding the co-prescription of gabapentinoids with opioids, suggesting a potential increased risk of adverse outcomes. This has prompted advisories to exercise caution when combining these medications.
  • Renal Impairment: Dosage adjustments are necessary for patients with renal impairment, a standard clinical consideration.
• Therapeutic Guidelines: Inclusion and positioning of gabapentin within treatment algorithms for epilepsy and neuropathic pain by professional organizations (e.g., American Academy of Neurology, American Epilepsy Society) influence prescribing habits. Gabapentin is often a first or second-line agent for neuropathic pain and a standard adjunctive therapy for certain seizure types.

What are the Market Challenges and Opportunities?

The gabapentin market faces distinct challenges and presents specific opportunities for stakeholders.

• Challenges:
  • Intense Generic Competition: The highly competitive generic market exerts significant downward pressure on pricing, reducing profit margins for manufacturers.
  • Price Erosion: Continuous generic entry and purchasing consortiums drive down prices for gabapentin.
  • Stricter Prescribing Controls: Potential for increased regulatory scrutiny and monitoring of gabapentinoid prescriptions could curb off-label use or necessitate more detailed patient evaluation.
  • Development of Alternative Therapies: Ongoing research into novel mechanisms of action for pain and seizure management could lead to the introduction of superior treatment options.
  • Public Perception and Abuse Concerns: Negative publicity surrounding gabapentinoid abuse can influence physician and patient attitudes.
• Opportunities:
  • Cost-Effective Treatment: Gabapentin remains a cornerstone for cost-effective management of chronic pain and epilepsy, particularly in resource-limited settings or for patients requiring long-term treatment.
  • Expanded Off-Label Use: Continued research and clinical experience may validate further off-label applications, creating new market segments.
  • Formulation Innovation: While challenging post-patent expiry, development of novel delivery systems or combination therapies involving gabapentin could create differentiated products, though significant market impact is unlikely without substantial clinical advantages.
  • Emerging Markets: Growth in healthcare infrastructure and access in developing economies can expand the demand for essential medications like gabapentin.
  • Combination Therapies: Exploring synergistic effects with other therapeutic agents could lead to new treatment approaches, although this would likely require significant clinical trial investment.

Key Takeaways

• Brand-name Neurontin sales are minimal due to patent expiry and the ubiquity of generic gabapentin.
• The generic gabapentin market is substantial and projected for steady growth, driven by its established efficacy and cost-effectiveness in treating epilepsy and neuropathic pain.
• Key market drivers include the rising prevalence of neurological disorders and the affordability of generic formulations.
• Potential restraints include the drug's side effect profile, the emergence of newer therapies, and regulatory concerns regarding abuse and misuse.
• While core patents have expired, ongoing clinical use and potential for off-label applications sustain the gabapentin market.

Frequently Asked Questions

1. Will Pfizer discontinue Neurontin? Pfizer continues to market Neurontin, but its sales volume is negligible compared to the overall gabapentin market. Discontinuation is unlikely in the short term, but its market relevance is minimal.

2. What is the average price of generic gabapentin? The average price of generic gabapentin varies significantly by dosage, form (capsule, tablet, oral solution), and pharmacy. However, prices are generally very low, often ranging from $0.10 to $0.50 per daily dose, making it highly accessible.

3. Are there any new patent protections for gabapentin? The primary composition of matter patents for gabapentin have expired. While secondary patents on specific formulations or methods of use might exist, they are unlikely to prevent generic competition for the core indication.

4. What are the most significant side effects associated with gabapentin? Common side effects include dizziness, somnolence (drowsiness), fatigue, ataxia (lack of coordination), and peripheral edema. More serious side effects can include suicidal thoughts, severe skin reactions, and respiratory depression, particularly when used with opioids.

5. How does gabapentin compare to pregabalin (Lyrica)? Gabapentin and pregabalin are both gabapentinoids used for neuropathic pain and epilepsy. Pregabalin is generally considered more potent and may have a more favorable pharmacokinetic profile in some respects, leading to less frequent dosing. However, pregabalin is typically more expensive, and its patent protections have also largely expired, leading to generic competition.

Citations

[1] Pfizer Inc. (Annual Reports, various years). Company financial filings. U.S. Securities and Exchange Commission. [2] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA Orange Book website] [3] IQVIA. (Data access and reports, various years). National Prescription Drug Audit (NPDA). (Proprietary Market Data). [4] U.S. Food and Drug Administration. (n.d.). Neurontin (gabapentin) prescribing information. [5] Warner-Lambert Co. v. Teva Pharmaceuticals USA, Inc., 539 U.S. 155 (2003). [6] Grand View Research. (2023). Gabapentin Market Size, Share & Trends Analysis Report. [7] U.S. Food and Drug Administration. (2019, July 23). FDA Drug Safety Communication: FDA investigating potential risks of using gabapentinoids and opioids together.